Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 3/20 | 0.94 |
| ▸ | MAPT | P10636 | 2/20 | 0.94 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.94 |
| ▸ | HPGD | P15428 | 1/20 | 0.94 |
| ▸ | CNR1 | P21554 | 1/20 | 0.94 |
| ▸ | CNR2 | P34972 | 1/20 | 0.94 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.73 |
| ▸ | PRKCA | P17252 | 2/20 | 0.72 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.72 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.72 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.72 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30863743 | 0.98 | MAPT (0.91) | FAAHMAPTALDH1A1HPGDCNR1 | |
| SCHEMBL23782661 | 0.98 | MAPT (0.91) | FAAHMAPTALDH1A1HPGDCNR1 | |
| SCHEMBL4572639 | 0.98 | MAPT (0.91) | FAAHMAPTALDH1A1HPGDCNR1 | |
| SCHEMBL29582801 | 0.98 | MAPT (0.91) | FAAHMAPTALDH1A1HPGDCNR1 | |
| SCHEMBL145068 | 0.98 | MAPT (0.91) | FAAHMAPTALDH1A1HPGDCNR1 | |
| 2-Arachidonoylglycerol SCHEMBL136277 | 0.97 | FAAH (1.00) | FAAHMAPTALDH1A1HPGDCNR1 | |
| 2-Arachidonoylglycerol SCHEMBL3685146 | 0.97 | FAAH (1.00) | FAAHMAPTALDH1A1HPGDCNR1 | |
| 2-Arachidonoylglycerol SCHEMBL136278 | 0.97 | FAAH (1.00) | FAAHMAPTALDH1A1HPGDCNR1 | |
| 2-Arachidonoylglycerol SCHEMBL18062264 | 0.97 | FAAH (1.00) | FAAHMAPTALDH1A1HPGDCNR1 | |
| SCHEMBL29575039 | 0.95 | FAAH (0.97) | FAAHMAPTALDH1A1HPGDCNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250298020-A1 | BIOMARKERS FOR MYCOBACTERIUM BOVIS | ABERYSTWYTH UNIVERSITY (GB) | 2025-09-25 | — | — | US | claimed |
| EP-4519684-A1 | BIOMARKERS FOR MYCOBACTERIUM BOVIS | Aberystwyth University (GB) | 2025-03-12 | — | — | EP | claimed |
| CN-118655239-A | MMD and ICAD distinguishing method based on lipidomic | 复旦大学 | 2024-09-17 | — | — | CN | claimed |
| CN-118318765-A | Metabolic-science-based breeding method for urechis unicinctus fast-growing strain | 中国科学院烟台海岸带研究所 | 2024-07-12 | — | — | CN | claimed |
| WO-2023214177-A1 | BIOMARKERS FOR MYCOBACTERIUM BOVIS | ABERYSTWYTH UNIVERSITY (GB) | 2023-11-09 | — | — | WO | claimed |
| US-20250298020-A1 | BIOMARKERS FOR MYCOBACTERIUM BOVIS | ABERYSTWYTH UNIVERSITY (GB) | 2025-09-25 | — | — | US | disclosed |
| US-20250298020-A1 | BIOMARKERS FOR MYCOBACTERIUM BOVIS | ABERYSTWYTH UNIVERSITY (GB) | 2025-09-25 | — | — | US | disclosed |
| EP-4519684-A1 | BIOMARKERS FOR MYCOBACTERIUM BOVIS | Aberystwyth University (GB) | 2025-03-12 | — | — | EP | disclosed |
| CN-118655239-A | MMD and ICAD distinguishing method based on lipidomic | 复旦大学 | 2024-09-17 | — | — | CN | disclosed |
| CN-118318765-B | Metabolic-science-based breeding method for urechis unicinctus fast-growing strain | 中国科学院烟台海岸带研究所 | 2024-09-17 | — | — | CN | disclosed |
| CN-118318765-A | Metabolic-science-based breeding method for urechis unicinctus fast-growing strain | 中国科学院烟台海岸带研究所 | 2024-07-12 | — | — | CN | disclosed |
| US-11929171-B2 | Methods for evaluation and treatment of glycemic dysregulation and atherosclerotic cardiovascular disease and applications thereof | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2024-03-12 | — | — | US | disclosed |
| WO-2023214177-A1 | BIOMARKERS FOR MYCOBACTERIUM BOVIS | ABERYSTWYTH UNIVERSITY (GB) | 2023-11-09 | — | — | WO | disclosed |
| US-20100113810-A1 | Treatment of neurodegenerative conditions | BTG INTERNATIONAL LIMITED (GB) | 2010-05-06 | — | — | US | disclosed |
| US-20090023807-A1 | Treatment of Cytokine Dysregulation by Using Sn-2 Gamma-Linolenoyl, Gamma-Diho-Molinolenoyl or Arachidonoyl Patty Acid Glycerol Monoesters | BTG INTERNATIONAL LIMITED | 2009-01-22 | — | — | US | disclosed |
| EP-1871352-A1 | TREATMENT OF CYTOKINE DYSREGULATION BY USING SN-2 GAMMA-LINOLENOYL, GAMMA-DIHOMOLINOLENOYL OR ARACHIDONOYL FATTY ACID GLYCEROL MONOESTERS | BTG International Limited (GB) | 2008-01-02 | — | — | EP | disclosed |
| WO-2006092622-A1 | TREATMENT OF CYTOKINE DYSREGULATION BY USING SN-2 GAMMA-LINOLENOYL, GAMMA-DIHOMOLINOLENOYL OR ARACHIDONOYL PATTY ACID GLYCEROL MONOESTERS | BTG INTERNATIONAL LIMITED (GB) | 2006-09-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090023807-A1 | Treatment of Cytokine Dysregulation by Using Sn-2 Gamma-Linolenoyl, Gamma-Diho-Molinolenoyl or Arachidonoyl Patty Acid Glycerol Monoesters | IL2, DAGLA, IFNG | FAAH 87/4885MAPT 4113/4885ALDH1A1 485/4885 |
| US-20100113810-A1 | Treatment of neurodegenerative conditions | DGAT2, ALOX12, DGKG | FAAH 56/4885MAPT 298/4885ALDH1A1 1038/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.